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ABSTRACT
The Cord Blood Transplantation Study (COBLT), sponsored by the National Heart, Lung, and Blood
Institute, is a phase II multicenter study designed to evaluate the use of cord blood in allogeneic transplan-
tation. In this report, we evaluated the outcomes of cord blood transplantation in 69 patients with lysosomal
and peroxisomal storage diseases. Patients with mucopolysaccharidoses I to III, mucolipidoses (ML) II (n 
36), adrenoleukodystrophy (n  8), metachromatic leukodystrophy (n  6), Krabbe disease (n  16), and
Tay-Sachs disease (n  3) were enrolled between August 1999 and June 2004. All patients received the same
preparative regimen, graft-versus-host disease (GVHD) prophylaxis, and supportive care. End points included
survival, engraftment, GVHD, and toxicity. Sixty-nine patients (64% men; 81% white) with a median age of 1.8
years underwent transplantation with a median cell dose of 8.7  107/kg. One-year survival was 72% (95%
confidence interval, 61%-83%). The cumulative incidence of neutrophil engraftment by day 42 was 78% (95%
confidence interval, 67%-87%) at a median of 25 days. Grade II to IV acute GVHD occurred in 36% of patients.
Cord blood donors are readily available for rapid transplantation. Cord blood transplantation should be
considered as frontline therapy for young patients with lysosomal and peroxisomal storage diseases.
© 2006 American Society for Blood and Marrow Transplantation
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nNTRODUCTION
Inherited metabolic storage diseases are a hetero-
eneous group of rare disorders due to mutations that
ause deﬁciencies in various enzymes, thus resulting in
n accumulation of toxic metabolites in various tissues.
subset of these conditions, lysosomal and peroxiso-
al storage diseases (LSDs), is characterized by severe
eurologic deterioration and eventual death in the
rst or second decade of life. LSDs can be divided into
he mucopolysaccharidoses, which are characterized
y an accumulation of glycosaminoglycans, causing g
84amage to the brain, heart, cornea, cartilage, liver, and
ther organs, and sphingolipidoses or leukodystro-
hies, which are characterized by defects in lysosomal
cid hydrolases involved in sphingolipid catabolism,
esulting in demyelination in the central and periph-
ral nervous systems.
Allogeneic stem cell transplantation can prevent
he progression of LSD symptoms by providing a
ontinuous source of normal enzymes from engrafted
onor cells, provided that the enzyme is produced by
ormal leukocytes [1]. Over the past 2 decades, allo-
eneic bone marrow transplantation from matched
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CBT and Lysosomal Storage Diseases
Belated carrier and noncarrier donors has been shown
o be beneﬁcial in 200 patients with Hurler syn-
rome [1-13] and others with adrenoleukodystrophy,
etachromatic leukodystrophy [14-19], and Krabbe
isease (globoid leukodystrophy) [20-22].
Many children with LSDs who could beneﬁt from
llogeneic transplantation therapy lack an appropriately
atched donor. Partially HLA-matched, banked, unre-
ated donor umbilical cord blood can provide donor
tem cells for transplantation of children with either
alignancies or inherited diseases who lack suitable
one marrow donors [23-26]. Between 2000 and 2004,
he Cord Blood Transplantation Study (COBLT),
ponsored by the National Heart, Lung, and Blood
nstitute, National Institutes of Health, investigated
he safety and feasibility of unrelated donor umbilical
ord blood transplantation (CBT) in children and
dults with lymphohematologic disorders and in 69
oung children with LSDs. We describe in this article
he results for the patients with LSD.
ATERIALS AND METHODS
atients
Between August 1999 and June 2004, 69 children
ith LSDs who lacked HLA-matched related donors
ere treated with unrelated donor umbilical CBT.
lthough the COBLT study is a multicenter study, 67
f the 69 patients enrolled were treated at a single insti-
ution (Duke University). Thirty-one patients were con-
ecutively entered on the LSD stratum of the COBLT
rotocol between August 1999 and July 2002. Once
ccrual was reached in the LSD stratum, the stratum
as closed. Subsequent patients who met entry crite-
ia could obtain a COBLT unit and be treated under
he expanded access protocol (EAP). An additional 38
ere consecutively entered under the EAP between
uly 2002 and June 2004. The criteria for study en-
ollment and the treatment plans were identical for
oth groups.
The diagnosis of LSD was conﬁrmed by the lack
f speciﬁc enzyme activity in peripheral blood leuko-
ytes or ﬁbroblasts. Institutional review boards ap-
roved the protocols at each participating center, and
he parents of each patient provided written informed
onsent before study enrollment. Results in children
ith Hurler syndrome (14 of whom were also in-
luded in this article) and Krabbe disease (4 patients in
his article) have been previously reported [26,27].
Patients diagnosed with LSD whose developmen-
al quotient, IQ, or clinical neurodevelopment exam-
nation demonstrated a level of functioning at which
ontinuous life support would not be predicted to be
equired in the year after transplantation were eligible
or enrollment. Patients with a Lansky performance
core 50%, primary myeloﬁbrosis, or suitable re- o
B&MTated donors were ineligible. Patients with prior allo-
eneic stem cell transplantation within 12 months or
utologous transplantation within 6 months were ex-
luded, as were individuals with uncontrolled bacte-
ial, viral, or fungal infections. Multiorgan assessment
erformed before enrollment was required to demon-
trate the following: serum creatinine normal for age
r a creatinine clearance 50% of the lower limits of
ormal for age; aspartate aminotransferase 5 times
he upper limits of normal and total serum bilirubin
2.5 mg/dL; cardiac status asymptomatic or left ven-
ricular ejection fraction 40% that improved with
xercise; and asymptomatic pulmonary function or
arbon monoxide diffusion in the lung, forced expira-
ory volume in 1 second, and diffusion capacity45%
f predicted (corrected for hemoglobin) or oxygen
aturation 85% on room air. The selected cord
lood unit (CBU) was required to provide a minimum
f 1  107 total nucleated cells (NCs; before cryo-
reservation) per kilogram of recipient weight.
election of Donors
Searches for CBUs from unrelated donors were
onducted by using low-/intermediate-resolution mo-
ecular typing for HLA matching class I (A and B) and
igh-resolution molecular typing for HLA-DRB1.
he CBU was selected that provided the highest
umber of NCs and matched at a minimum of 4 of 6
LA loci. A unit matched at 3 of 6 alleles could be
elected if the match was based on high-resolution
yping of HLA-A, -B, and -DRB1 and if there was at
east 1 match per locus. In most cases (n  61),
nzyme testing on a sample of the cord blood donor
ells or plasma was tested for the enzyme lacking in
he intended recipient to ensure that affected or car-
ier donors were not selected.
ransplantation Procedure
COBLT CBUs were thawed as described in the
OBLT manual of procedures (http://spitﬁre.
mmes.com/study/cord/). Cryopreserved CBUs from
ther banks were thawed and processed according to
he thawing instructions provided by the cord blood
ank. NCs, clonal hematopoietic progenitor cells, and
D3 and CD34 cells were counted, ABO and Rh
yping were performed, cell viability was assessed, and
acterial and fungal cultures were obtained at the time
f banking and again at the time of thawing and
nfusion of the cord blood donor cells. Cells were
nfused intravenously (IV) over 10 to 30 minutes after
remedication with diphenhydramine, acetamino-
hen, and steroids.
onditioning Regimen
All patients were prepared for transplantation with
ral busulfan (20-40 mg/m2 per dose, with dosing
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1ased on patient age) for 16 doses on days9 through
6, cyclophosphamide 50 mg/kg per dose IV on days
5 through 2, and antithymocyte globulin (ATG;
harmacia & Upjohn, Kalamazoo, MI) 30 mg/kg per
ose IV on days 3 through 1. First-dose pharma-
okinetics were measured for busulfan, and a concen-
ration steady state of 600 to 900 ng/mL was targeted.
henytoin was given during busulfan therapy to pre-
ent seizures, mesna was given during cyclophospha-
ide therapy to prevent hemorrhagic cystitis, and
ethylprednisolone, acetaminophen, and diphenhy-
ramine were given before and during ATG therapy
o prevent hypersensitivity reactions. The cord blood
as infused on day 0.
rophylaxis against Graft-versus-Host Disease
All patients received cyclosporine for 9 months
nd methylprednisolone for 2 to 3 months as prophy-
axis against graft-versus-host disease (GVHD). Cy-
losporine was dosed to maintain levels of 200 to 400
g/mL. Corticosteroids were given at 1 mg/kg/d on
ays 0 to 4 and 2 mg/kg/d on day 5 until the minimum
f day 21 or engraftment and were then tapered at
.2 mg/kg/wk. Patients with grade I acute GVHD
ere treated with topical creams, whereas patients
ith grades II and above received a high-dose meth-
lprednisolone pulse (500 mg/m2 per dose IV every 12
ours four 4 doses). Most patients whose GVHD did
ot respond or whose disease recurred after the ste-
oid pulse were changed to tacrolimus with or without
aclizumab.
upportive Care
All patients were hospitalized and maintained in
everse isolation under high-energy particulate air ﬁl-
ration and positive-pressure ventilation. Prophylaxis
gainst Pneumocystis carinii, viral, and fungal infections
as administered to all patients while they remained
n immunosuppressive therapy. Empiric treatment
ith broad-spectrum IV antibiotics was started with
he ﬁrst episode of neutropenic fever and continued
ntil neutropenia resolved. For immunoprophylaxis,
V immunoglobulin was administered weekly at a dose
f 500 mg/kg per dose through posttransplantation
ay 100 and then monthly for most of the ﬁrst post-
ransplantation year. Low-dose continuous infusion
eparin was administered IV from the initiation of the
reparative regimen through posttransplantation day
8 for prophylaxis against veno-occlusive disease. All
atients were supported as needed with transfusions of
eukocyte-depleted, irradiated packed red blood cells
nd platelets. Filgastrim (Amgen, Thousand Oaks,
A) was administered IV from day 0 until engraft-
ent of donor cells. t
86tudy End Points and Statistical Analysis
The primary end point of the study was survival at
80 days after transplantation. The secondary end-
oints included engraftment (neutrophil and platelet),
cute and chronic GVHD, and regimen-related mor-
idity and mortality.
Neutrophil engraftment was deﬁned as achieving an
bsolute neutrophil count (ANC) of at least 500/L for
consecutive measurements on different days and dem-
nstrated donor chimerism of90%. Primary graft fail-
re was deﬁned as failure to attain neutrophil engraft-
ent by day 42. Patients who survived to day 14 and died
efore neutrophil engraftment were classiﬁed as primary
raft failures. Hematopoietic recovery was deﬁned as an
NC of at least 500/L for 3 consecutive measurements
n different days without demonstrated donor chimer-
sm 90%. Secondary graft failure was deﬁned as a loss
f neutrophil engraftment. The platelet engraftment
ate was deﬁned as the ﬁrst of 3 consecutive days with a
latelet count 20 000/L unsupported by platelet
ransfusion for a minimum of 7 days. The time to
eutrophil or platelet engraftment was deﬁned as the
ime from transplantation to the ﬁrst day of engraft-
ent.
Clinically signiﬁcant infections were reported af-
er transplantation by the site of infection, organism,
nd severity of infection. Readmissions after the initial
ischarge for the transplantation were reported by
ate and primary and secondary reasons for admission.
he Bearman toxicity scale was used to report maxi-
um regimen-related toxicity by day 42 after trans-
lantation [28]. The staging of acute GVHD followed
ational Marrow Donor Program guidelines and in-
luded weekly capture of symptoms through day 100
nd at days 120 and 150 with characterization of
lternative causes. The grading of acute GVHD fol-
owed the GVHD consensus grading scheme [29]. An
lgorithm calculated the maximum GVHD clinical
rade on the basis of the weekly organ staging in skin,
pper and lower gastrointestinal tract, and liver. This
alculated organ stage was decreased by 1 stage if a
isted speciﬁc differential diagnosis was reported for
ither the gastrointestinal tract or liver. An indepen-
ent panel reviewed weekly records and assigned each
atient a ﬁnal maximum grade; this is similar to the
ethods described by Weisdorf et al. [30].
Primary causes of death were reported by follow-
ng the hierarchy developed for the Unrelated Donor
arrow Transplantation Trial (http://spitﬁre.emmes.
om/study/tcd/). The hierarchy was developed by an
xpert panel and was based on reﬁnements to the
ational Marrow Donor Program hierarchy for re-
orting causes of death. The hierarchy requires that
raft failure or GVHD be reported as the primary
ause of death, rather than another condition’s leading
o death, such as infection, organ failure, or hemor-
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CBT and Lysosomal Storage Diseases
Bhage. It also provides rules for reporting secondary
auses of death.
Survival estimates were calculated by using the
aplan-Meier method [31]. Testing for differences in
urvival between groups in the univariate analysis used
he log-rank test. Variables considered in the univariate
nalysis included age, sex, ethnicity, donor ethnicity,
rimary disease, performance status, HLA matching,
retransplantation cytomegalovirus serostatus, weight,
C dose, CD34 dose, CD3 dose, and protocol. Cox
roportional hazard models were used for multivariate
nalysis of survival [32]. Neutrophil and platelet re-
overies, acute GVHD, and chronic GVHD were
nalyzed by using the cause-speciﬁc failure probability
ethod (or cumulative incidence), in which death and
econd infusion were treated as competing risks [33].
he complement of the Kaplan-Meier (1  KM)
stimate for these end points was used to calculate the
umulative probability. No imputation was used for
ny missing data. Frequency data in cross-tabulation
ables were compared by using the 2 or Kruskal-
allis test. All analyses were performed with SAS
oftware, version 8.2 (SAS Institute Inc., Cary, NC).
etrospective HLA Typing
High-resolution molecular typing for HLA-A and
B became available after the study was initiated. To
etermine the effect of this typing information on
atient outcome, high-resolution typing for HLA-A,
LA-B, and HLA-DRB1 alleles was performed for 60
onor/recipient pairs (subsequently referred to as ﬁnal
LA typing). The results of statistical analyses by us-
ng this information was compared with the results in
hich HLA-A and -B typing was performed with
ow-/intermediate-resolution HLA typing.
ESULTS
atient Characteristics
Sixty-nine patients were analyzed in this study.
able 1 shows the baseline characteristics of all pa-
ients. The age at the time of transplantation ranged
rom 0.1 to 11.7 years, with a median of 1.8 years.
wo thirds of the patients were men, 19% were white,
nd one third had a Lansky performance score of80.
wenty-ﬁve percent of patients were cytomegalovirus
eropositive before transplantation. Using original HLA
riteria (low- to intermediate-resolution molecular typ-
ng at class I A and B and high-resolution typing at HLA
lass II DRB1), 90% of patients received anHLA 5/6- or
/6-matched graft. Forty-one percent of the HLA 4/6-
atched and 26% of the HLA 5/6-matched grafts were
owngraded by retrospective high-resolution molecular
yping (Table 2). The median NC dose was 8.7  107,
he CD3 dose was 1.5  107, and the CD34 cell
ose was 2.4  105. b
B&MTAs seen in Table 1, the characteristics of the pa-
ients on the LSD stratum were very similar to those
f the patients on the EAP stratum. The LSD stratum
howed slightly better performance status. The EAP
ohort also had more men, more white patients, and
lightly worse HLA matches. However, none of these
ifferences was statistically signiﬁcant. No patient
ith metachromatic leukodystrophy was treated in the
SD stratum, whereas 6 of the 38 patients in the EAP
roup had this diagnosis; similarly, only 2 patients in
he LSD stratum had Sanﬁlippo syndrome, and 8
atients in the EAP group had this diagnosis (P 
003).
Overall survival at 180 days was 80% (95% con-
dence interval [CI], 71%-90%) and 72% (95% CI,
1%-83%) at 1 year. Long-term survival was 68%
ith a median follow-up time of 24.5 months (range,
.9-58.5 months; Figure 1A). Nonwhite ethnicity was
igniﬁcantly associated with lower survival (P  .03;
igure 1B). It made little difference whether recipient or
onor ethnicity was considered, because at the broad
evel of white versus nonwhite, there was a very high
orrelation between donor and recipient ethnicity.
Patients on the EAP stratum had signiﬁcantly
orse survival than LSD stratum patients (Figure 1C;
 .024). One-year survival was 81% (95% CI, 67%-
5%) for LSD stratum patients but only 64% (95%
I, 47%-80%) for EAP patients (Figure 1C). The
xplanation seems to be related to the lower perfor-
ance status of patients on the EAP stratum (Table 1).
he proportions with a Lansky score 80 were 16
42%) of 38 for the EAP and 8 (26%) of 31 for the
SD stratum, and more patients with Sanﬁlippo and
etachromatic leukodystrophy (MLD) were on the
AP (n 14 versus n 2 on the LSD stratum). Other
actors, such as age, cell dose, CD34 cell dose, and
erformance status, did not exhibit a statistically sig-
iﬁcant association with survival. In contrast to what
as observed in young children with malignancy who
lso received nonlimiting CD34 cell doses, the ﬁnal
LA typing did not affect overall survival (Figure
D). In a Cox proportional hazards regression model,
nly ethnicity and study cohort (LSD stratum versus
AP) had signiﬁcant effects on survival.
The primary cause of death (Table 3) was reported
s acute GVHD (n  5), graft failure or autologous
ecovery (n  8), infection (bacterial, n  1; polyor-
anism, n  2), pulmonary failure (n  1), and other
auses (progressive disease, n  2; refractory hemo-
ytic anemia, n  1). Infection was a contributing
ause of death for 10 patients whose primary cause of
eath was acute GVHD, graft failure, or autologous
ecovery. Eighteen of these 20 deaths occurred in the
rst 8 months after transplantation, and 2 additional
eaths occurred at 13 and 21 months as a result of
acterial infection and autologous recovery followed
y an aspergillus infection.
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1eutrophil Engraftment
The median time to neutrophil engraftment with
ocumented donor cells 90% was 25 days (95% CI,
2-30 days). Fifty-four patients achieved neutrophil
ngraftment by day 42, and an additional 4 patients
able 1. Baseline Characteristics of 69 Cord Blood Recipients with Lyso
Variable
LSD*
Median Rang
atient age (y) 1.8 0.1-9.3
atient weight (kg) 12.0 3.9-42
otal viable NCs3 (107/kg) 8.7 2.8-38
nfused NCs (107/kg) 7.1 2.5-24
D34 cell dose (105/kg) 2.7 0.4-13
D3 cell dose (107/kg) 1.5 0.5-7.7
N %
ecipient sex
Male 17 55
Female 14 45
ecipient ethnicity
White 23 74
Black 3 10
Asian 1 3
Hispanic 1 3
Mixed/other/unknown 3 10
rimary disease
Hurler syndrome (MPS I) 13 42
Hurler-Scheie syndrome 2 6
Hunter syndrome (MPS II) 0 0
Sanfilippo syndrome (MPS III) 2 6
I cell disease (ML II) 1 3
Globoid cell leukodystrophy 7 23
Adrenoleukodystrophy 4 13
Metachromatic
leukodystrophy 0 0
Tay-Sachs syndrome 2 6
ansky performance status
<80 8 26
90 11 35
100 12 39
riginal HLA match
6/6 3 10
5/6 12 39
4/6 15 48
3/6 1 3
inal HLA match
6/6 2 6
5/6 7 23
4/6 11 35
3/6 9 29
2/6 1 3
Missing 1 3
onor/recipient sex
Male/male 10 32
Male/female 7 23
Female/male 6 19
Female/female 8 26
retransplantation CMV status
Positive 9 29
Negative 22 71
C indicates nucleated cell; CMV, cytomegalovirus.
Lysosomal and peroxisomal storage disease stratum.
Expanded access protocol stratum.ngrafted on days 47, 48, 49, 51. Three (4%) of the 7
88atients with graft failure had ANC hematopoietic
ecovery without documented donor chimerism.
The cumulative incidence estimate of engraftment
y day 42 was 78% (95% CI, 67%-87%). By day 100,
he probability of engraftment was 84% (95% CI,
iseases
EAP† Total
Median Range Median Range
1.9 0.1-11.7 1.8 0.1-11.7
12.8 4.0-34.6 12.3 3.9-42.3
9.3 3.0-26.5 8.7 2.8-38.8
7.0 2.7-20.7 7.1 2.5-24.3
2.2 0.5-12.9 2.4 0.4-13.3
1.5 0.3-3.7 1.5 0.3-7.7
N % N %
27 71 44 64
11 29 25 36
33 87 56 81
3 8 6 9
0 0 1 1
1 3 2 3
1 3 4 6
8 21 21 30
0 0 2 3
2 5 2 3
8 21 10 14
0 0 1 1
9 24 16 23
4 11 8 12
6 16 6 9
1 3 3 4
16 42 24 35
9 24 20 29
13 34 25 36
2 5 5 7
17 45 29 42
18 47 33 48
1 3 2 3
0 0 2 3
13 34 20 29
12 32 23 33
2 5 11 16
3 8 4 6
8 21 9 13
11 29 21 30
16 42 23 33
3 8 9 13
8 21 16 23
8 21 17 25
30 79 52 75somal D
e
.3
.8
.3
.35%-91%). As can be seen in Figure 2A, the cumula-
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CBT and Lysosomal Storage Diseases
Bive incidence estimate was only marginally lower than
he 1  KM estimate, because there was only 1 early
eath (at day 37). A higher CD3 dose (before cryo-
reservation) was signiﬁcantly associated with the in-
idence of engraftment (P  .006). The median time
o engraftment was 22 days for patients with a CD3
ose exceeding 1.5 107/kg and 32.5 days for patients
ith a CD3 dose below this level. A higher CD34
before cryopreservation) dose was suggestive (P 
051) of faster engraftment; however, none of the
ther factors considered demonstrated a statistically
igniﬁcant association with neutrophil engraftment,
ncluding age, sex, race, primary disease, HLA match,
eight, NC dose, or study cohort.
latelet Engraftment
Forty-nine of 69 patients achieved a platelet en-
raftment of 20 000/L, and 42 of 69 achieved a
latelet engraftment of 50 000 (results were not
nown in 1 case). The median time to a platelet
ngraftment of 20 000 was 88 days (95% CI, 67-108
ays) and was 103 days (95% CI, 83-174 days) to a
latelet engraftment of 50 000. The cumulative inci-
ence of platelet engraftment of 50 000 was 47%
95% CI, 37%-59%) at day 100 and 62% (95% CI,
1%-74%) at day 180 (Figure 2B). The corresponding
 KM estimates for a platelet engraftment of
0 000, in which competing risks were not taken into
ccount, were 52% (95% CI, 40%-65%) and 71%
95% CI, 59%-83%) at day 100 and 180, respectively
Figure 2B).
There was a weak indication of a statistical asso-
iation of platelet engraftment of 20 000 with donor
thnicity (P  .035). For platelet engraftment at a
evel of 50 000, the association with ethnicity was not
igniﬁcant, but the association with CD3 dose was
arginally signiﬁcant (P  .069). None of the other
ariables considered, including age, sex, race, primary
isease, HLA match, weight, NC dose, or study co-
ort, had a statistically signiﬁcant association with
latelet engraftment.
cute and Chronic GVHD
Six (9%) of 69 of patients experienced maximum
able 2. Final HLA Match by Original HLA Match
Original
HLA
Match
Final HLA Match*
2/6 3/6 4/6 5/6 6/6 All
3/6 1 (50) 1 (50) 0 (0) 0 (0) 0 (0) 2 (100)
4/6 3 (10) 9 (31) 17 (59) 0 (0) 0 (0) 29 (100)
5/6 0 (0) 1 (4) 6 (22) 20 (74) 0 (0) 27 (100)
6/6 0 (0) 0 (0) 0 (0) 0 (0) 2 (100) 2 (100)
All 4 (7) 11 (18) 23 (38) 20 (33) 2 (3) 60 (100)
ata are n (%).
Sixty of the 69 patients had high-resolution typing.cute GVHD grades of III or IV, whereas 25 (36%) of N
B&MT9 experienced grade II to IV acute GVHD. The
umulative incidence of acute GVHD grades II to IV
as 44% (95% CI, 33%-55%), and that of grades III
nd IV was 10% (95% CI, 4%-17%) at day 100. As
een in Figure 2C, the cumulative incidence was only
arginally lower than the 1  KM estimates because
here were only a few early deaths.
Lower weight was signiﬁcantly associated with de-
elopment of acute GVHD (P  .034). The day 100
stimate among patients with lower weight was 54%
95% CI, 37%-71%), versus 33% (95% CI, 18%-
2%) for weight 12 kg. Higher CD3 (P  .019)
nd CD34 (P  .060) cell doses were also associated
ith increased GVHD. At day 100, the cumulative
ncidences were 30% (95% CI, 18%-45%) and 58%
95% CI, 42%-74%) for CD3 doses .5  107/kg
nd1.5 107/kg, respectively. Similarly, at day 100,
he cumulative incidences were 34% (95% CI, 19%-
1%) and 54% (95% CI, 38%-72%) for a CD34
ose 2.4  105/kg and 2.4  105/kg, respectively.
lthough not statistically signiﬁcant, performance sta-
us was suggestive (P  .078) of more frequent acute
VHD.
Thirteen of 68 patients contracted chronic GVHD
etween 4 and 25 months after transplantation. Most of
hese cases (n  11) had a limited maximum grade
localized skin involvement, hepatic dysfunction, or
oth); 2 had extensive chronic GVHD. The cumula-
ive incidence of chronic GVHD was 8% at 6 months
nd 18% (95% CI, 8%-27%) at 1 year after transplan-
ation (Figure 2D).
oxicity
By day 42 after transplantation, 8 (12%) patients
ut of 69 had severe pulmonary toxicity, 7 (10%)
atients had severe central nervous system toxicity,
nd 4 (6%) had severe stomatitis. Moderate stomatitis
oxicity was evident in 54 (78%) patients, and moder-
te renal toxicity was evident in 26 (38%) patients
Figure 3). There was 1 fatal pulmonary toxicity.
ISCUSSION
We describe the results of a prospective trial of
nrelated CBT in 69 young children with a variety of
SDs. All patients received a common chemotherapy-
ased conditioning regimen, GVHD prophylaxis, and
upportive care. Most patients received HLA-mis-
atched grafts. Because of their young age and small
ize, relatively high doses of NCs, CD3 cells, and
D34 cells were administered to all patients. Over-
ll, there was excellent survival, with a plateau approx-
mately 2 years after transplantation.
In a similarly aged cohort of children with child-
ood leukemia who also received nonlimiting doses of
Cs, CD3 cells, and CD34 cells, we noted lower
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1igure 1. Survival for patients with lysosomal diseases. A, Overall survival. B, Survival by recipient race. C, Survival by study cohort (LSD
tratum versus EAP). D, Survival by ﬁnal HLA match.
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CBT and Lysosomal Storage Diseases
Bstimates of neutrophil recovery, grade III and IV
cute GVHD at day 100, and chronic GVHD [34].
otably, in that cohort, a higher-level HLA match
howed improved survival, and the difference was sta-
istically signiﬁcant when the ﬁnal high-resolution
LA-A, -B, and -DRB1 match was considered. In this
ohort, HLA matching by low- or high-resolution
riteria did not seem to affect engraftment, GVHD,
r survival; however, the small sample size may have
imited the ability to detect the inﬂuence of HLA in
his cohort.
Children with congenital disorders have not
een exposed to high doses of chemotherapy before
ytoreduction for transplantation and, thus, might
e considered to be at a higher risk for nonengraft-
ent than children with malignancies. This was not
he case in this study, in which patients received
TG, busulfan, and cyclophosphamide in the prepar-
tive regimen, as opposed to ATG, busulfan, and
elphalan in the leukemic cohort of patients. Cyclo-
hosphamide would be considered to be more immu-
osuppressive than melphalan, which was chosen for
ts antileukemic properties. Similar to what has been
bserved after unrelated marrow transplantation, chil-
ren with congenital disorders in this study had a low
ncidence of severe acute and chronic GVHD as com-
ared with young children with leukemia (N.A.K.,
npublished data).
Of note, in the cohort of young children with
eukemia, ethnicity did not affect survival, whereas
onwhite ethnicity correlated with poorer survival in
his study, although no obvious criteria emerged to
xplain this observation. The small sample size in this
tudy prevents any deﬁnitive analysis on this issue.
he effect of ethnicity on overall survival may reﬂect
ismatching of minor HLA antigens that is not mea-
urable with currently available techniques.
Patients treated on the EAP protocol had poorer
urvival as compared with those enrolled on the LSD
tratum. All patients were sequentially entered on the
tudy with identical selection criteria. The EAP pa-
ients were treated more recently, after the LSD stra-
able 3. Causes of Death
Primary Cause of Death
Contributing Total,
n (%)Infection No Infection
cute GVHD 4 1 5 (25)
utologous recovery 4 0 4 (20)
raft failure 2 2 4 (20)
nfection—polyorganism — — 2 (10)
nfection—bacterial — — 1 (5)
rgan failure—pulmonary — — 1 (5)
ther* — — 3 (15)
otal 10 3 20 (100)
Progressive disease (n  2) and refractory hemolytic anemia (n  1).um had closed to accrual. Although patients were not s
B&MTvaluated or treated any differently on the EAP, pa-
ients enrolled under the EAP had, by chance, a lower
erformance status, and more patients had a diagnosis
f Sanﬁlippo syndrome and MLD. The difference in
urvival between the 2 cohorts of patients may be an
rtiﬁcial observation related to the small numbers of
atients with varying diagnoses in both groups.
The results of this study conﬁrmed previously re-
orted observations from trials that used CBT in pa-
ients with LSDs. Despite signiﬁcant donor-recipient
LA mismatching, the incidence of acute grades II to
V GVHD was in an acceptable range. In this study,
e learned that patients with higher CD3 cell doses
ere at an increased risk for acute GVHD. Chronic
VHD occurred at a signiﬁcantly lower incidence
han would be expected in unrelated marrow trans-
lantation, and most patients had limited involvement
ithout signiﬁcant long-term sequelae. Overall, dura-
le donor cell engraftment was achieved in 84% of
atients. Because these patients were not exposed to
mmunosuppressive therapy before their condition-
ng therapy, the major reason for graft failure is host
ejection caused by failure of the preparative regi-
en to fully ablate host immunity. The addition
f ﬂudarabine, Campath-1H (Berlex, Inc,
ontville, NJ), or other non–cross-reactive im-
une-suppressing therapy to the preparative regi-
en could be considered in future trials to address
his obstacle to engraftment. More than half of the
atients enrolled on this study had a diagnosis of
ucopolysaccharidoses type 1 (MPS) syndrome.
hese patients have massive hepatosplenomegaly,
hich can interfere with engraftment by 2 mecha-
isms. First, immediately after infusion of donor
ells, cells can be trapped in the reticuloendothelial
ystem, thus resulting in a decrease in the adminis-
ered cell dose. Second, the liver, spleen, or both
an become a temporary site of extramedullary he-
atopoiesis, thus delaying neutrophil recovery.
trategies to induce endothelial blockade (eg, IV
mmunoglobulin before transplantation) could be
onsidered to address this problem. It is important
o note that no secondary graft failures have oc-
urred.
Donor availability is a major obstacle to bone
arrow transplantation, with 50% of patients un-
ble to identify a suitable adult stem cell donor in a
imely fashion. Banked umbilical cord blood is pro-
pectively HLA typed and screened for infections and
ther risk factors and is readily available for transplan-
ation. In this report, the average time from the onset
f a search to identiﬁcation of a compatible umbilical
BU (including screening of enzyme activity, when
pplicable) was 15 days. The time from search onset to
he beginning of the preparative regimen was 41 days
31 days in patients who underwent transplantation
ince 2000). In a disease for which the time from
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1igure 2. Cumulative incidence (CINC) of engraftment and GVHD. A, CINC and 1  KM probability of neutrophil engraftment. B, CINC
nd 1  KM probability of a platelet engraftment of 50 000. C, CINC and 1  KM probability of acute GVHD. D, CINC and 1  KM
robability of chronic GVHD.
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CBT and Lysosomal Storage Diseases
Biagnosis to deﬁnitive treatment may be crucial to
revent further disease progression, a source of stem
ells that can be acquired rapidly is extremely desir-
ble. Implementation of mandatory neonatal screen-
ng would allow for identiﬁcation of neonates who
ould be candidates for stem cell therapies at a time
hen maximal beneﬁt could be anticipated.
We did not address the effects of CBT on the
eurocognitive, language, and motor development of
hese patients. Results in children with Hurler syn-
rome (14 of whom were also included in this article)
nd Krabbe disease (4 patients in this article) have
een previously reported and have shown considerable
eneﬁt on neurocognitive outcomes, overall quality of
ife, and overall survival [26,27]. Because this article
epresents a mixture of patients with various LSDs at
ifferent stages of progression, it was not feasible to
ummarize these outcomes. However, after engraft-
ent and survival, the true efﬁcacy of this procedure
ill be measured in CBT’s ability to prolong life with
mproved quality of life. As more centers treat these
hildren, standardization of testing and supportive
herapies will be needed. Even with this short follow-
p, several of the children are already exceeding their
ife expectancies without transplantation.
In summary, we demonstrate that hematopoietic
tem cell transplantation with partially HLA-matched
nrelated donor banked umbilical cord is a viable
pproach to stem cell transplantation for patients with
SDs not amenable to other therapies. Engraftment
nd full donor chimerism were achieved and main-
ained without the use of total body irradiation. The
ncidence of acute and chronic GVHD was low. Do-
ors were readily and rapidly available. The overall
igure 3. Transplant-related toxicity. Maximal toxicity by organ
ystem is shown through day 42 as graded by the Bearman toxicity
cale [28]. The maximum toxicity experienced in any organ system
as 1 (1%) grade 0, 5 (7%) grade 1, 47 (68%) grade 2, 15 (22%)
rade 3, and 1 (1%) grade 4. CNS, central nervous system; GI,
astrointestinal.vent-free survival was very good. Although long- 1
B&MTerm follow-up and extensive neurocognitive studies
re needed to determine the full effect of umbilical
BT on the natural history of these syndromes, it is
lear that many patients will derive beneﬁt from this
herapy and that it should be considered for all young
atients diagnosed with LSDs amenable to transplan-
ation therapy who lack a matched related noncarrier
one marrow donor.
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